Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Sells $117,142.04 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 2,602 shares of the business’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $45.02, for a total transaction of $117,142.04. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $564,820.92. This represents a 17.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kiniksa Pharmaceuticals International Trading Up 1.2%

Shares of Kiniksa Pharmaceuticals International stock opened at $43.09 on Friday. The company has a 50-day moving average of $41.81 and a two-hundred day moving average of $38.23. Kiniksa Pharmaceuticals International, plc has a 12-month low of $18.12 and a 12-month high of $45.50. The stock has a market cap of $3.27 billion, a PE ratio of 95.76 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The firm had revenue of $180.86 million for the quarter, compared to analysts’ expectations of $166.64 million. During the same period last year, the firm earned ($0.18) EPS. Kiniksa Pharmaceuticals International’s revenue was up 61.2% compared to the same quarter last year. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of the company. Arrowstreet Capital Limited Partnership acquired a new stake in Kiniksa Pharmaceuticals International during the second quarter worth approximately $20,349,000. Qube Research & Technologies Ltd lifted its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. Rubric Capital Management LP boosted its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after purchasing an additional 447,536 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in Kiniksa Pharmaceuticals International by 288.6% in the fourth quarter. SG Americas Securities LLC now owns 541,396 shares of the company’s stock valued at $22,333,000 after purchasing an additional 402,078 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on KNSA shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a report on Friday, October 17th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Finally, Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.33.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.